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We thank Drs Nosotti, Simone, and
Cioffi for their kind remarks and excel-
lent commentary regarding our recent
publication.1 Endobronchial ultrasound-
guided transbronchial needle aspiration
(EBUS-TBNA) is truly an emerging
technology that allows safe and accu-
rate assessment of the mediastinum
in patients with non–small cell lung
cancer. We also anticipate the results
of the ASTER trial2 with hopes that it
will further validate our findings.
We also understand the valid point
made regarding the utility of rapid on-
site evaluation during EBUS-TBNA.
To this end, recent studies have sought
to investigate the utility of rapid on-site
evaluation.3,4 However, in a practical
sense, it may not always be possible
to have access to the service of an
experienced cytopathologist at all
times during the performance of
EBUS-TBNA. Practice patterns ulti-
mately are developed with the re-
sources that are available within
a given institution.
Altogether, EBUS-TBNA provides
a safe and reliable method of assessing
the mediastinum in patients with non–
small cell lung cancer. Whether the
results are available instantaneously or
in a couple of days, what matters the
most is achieving an accurate result.
Benjamin E. Lee, MD
Robert J. Korst, MD
The Daniel and Gloria Blumenthal
Cancer Center
Paramus, NJ
The Division of Thoracic Surgery
Department of Surgery
The Valley Hospital/Valley Health
System
Ridgewood, NJ278 The Journal of Thoracic and CReferences
1. Lee BE, Kletsman E, Rutledge JR, Korst RJ. Utility
of endobronchial ultrasound-guided mediastinal
lymph node biopsy in patients with non-small cell
lung cancer. J Thorac Cardiovasc Surg. 2012;143:
585-90.
2. Tournoy KG, Dooms CA, Rintoul RC, et al. A ran-
domized trial comparing endosonography followed
by surgical staging versus surgical mediastinal
staging alone in non-small cell lung cancer: the
ASTER study. J Clin Oncol. 2010;28:15s.
3. Griffin AC, Schwartz LE, Baloch ZW. Utility of on-
site evaluation of endobronchial ultrasound-guided
transbronchial needle aspiration specimens. Cyto-
journal. 2011;8:20.
4. Monaco SE, Schuchert MJ, Khalbuss WE. Diag-
nostic difficulties and pitfalls in rapid on-site eval-
uation of endobronchial ultrasound guided fine
needle aspiration. Cytojournal. 2010;7:9.
doi:10.1016/j.jtcvs.2012.04.011BENEFITS AND RISKS OF
USINGCLOPIDOGREL BEFORE
CORONARYARTERY BYPASS
SURGERY: A ROLE OF
PLATELET FUNCTION
ASSESSMENT
To the Editor:
We read with great interest the re-
cently published systematic review
and meta-analysis of randomized trials
and observational studies by Biancari
and colleagues.1 When assessing the
influence of preoperative antiplatelet
therapy (APT) administration manage-
ment on bleeding and adverse ischemic
events, the objective quantification of
platelet activity should inextricably be
included in the considerations. Ex-
pected inhibition of platelet function
is not always achieved after APT
administration. The frequency of low
responsiveness to aspirin and clopidog-
rel has been reported to range from 1%
to 45% for the 2 drugs.2 The efficacy of
platelet inhibition with aspirin and clo-
pidogrel varies widely among patients,
from intensive platelet inhibition to
poor platelet response. The effect of
clopidogrel on bleeding mainly de-
pends on2 factors: (1) observedplatelet
inhibition, which depends on inherent
platelet activity before clopidogrel
administration and platelet inhibitory
response to clopidogrel, and (2) the
ability of newborn platelets to restore
normal aggregation after clopidogrelardiovascular Surgery c July 2012discontinuation. This results in individ-
ual widespread variability in the activ-
ity of adenosine diphosphate platelet
receptors, which consequently reflects
similar variability in proclivity to ex-
cessive bleeding or adverse ischemic
events. Awidi and colleagues3 found
that the combination of aspirin and
clopidogrel had greater inhibitory
effects on platelet aggregation than ei-
ther agent alone. There is evidence
that certain patients have an accentu-
ated response to the usual doses of pre-
operative aspirin that may result in
increased perioperative blood loss.4
Therefore, the benefits and risks of us-
ing clopidogrel before coronary artery
bypass grafting (CABG) should be in-
dividually assessed according to plate-
let function tests, and the role of
aspirin should inevitably be included
in the considerations. For patients re-
ceiving dual APT (aspirinþ clopidog-
rel) before CABG, the influence of
aspirin on bleeding and ischemic ad-
verse events should be examined sepa-
rately using anaspirin-sensitive platelet
function test. The role of aspirin and
clopidogrel should be assessed sepa-
rately by drug-specific platelet func-
tion tests to provide the most precise
and reliable information on the benefits
and risks of preoperative administra-
tion for each antiplatelet agent, thus
facilitating an individual approach to
patients with the aim of reducing
bleeding and adverse ischemic events.
Evaluation of the effect ofAPT (aspirin
or clopidogrel) on both bleeding and is-
chemic events should be based on
platelet function assessment with sub-
sequent distinction of patients with
high residual platelet activity, thus
a proclivity to ischemic events, or
enhanced platelet inhibition, thus a pro-
clivity to excessive bleeding. Thegroup
of patients with pronounced platelet in-
hibition observed during APT could
benefit from early preoperative APT
withdrawal in terms of excessive bleed-
ing prevention. For patients undergoing
CABG, individually tailored APT ad-
ministration management based on
platelet function tests, both pre- and
Letters to the Editorpostoperatively, can help reduce both
bleeding and ischemic events. Such an
approach requires further studies to
provide a precise and comprehensive
view on the relationship between APT
administrationmanagement and bleed-
ing and ischemic events through
achieved platelet inhibition quantified
by platelet function tests.
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REPLACEMENT TO PREVENT
PATIENT–PROSTHESIS
MISMATCH IN THE ERA OF
VALVE-IN-VALVE
IMPLANTATION
To the Editor:
Patient–prosthesis mismatch (PPM)
is a matter of intense debate in cardiac
surgery. Although there is general sup-
port for the ‘‘bigger is better’’ hypoth-
esis,1 no uniform conclusion can be
drawn about the impact of PPM on
clinical outcome because results areThe Journalinconsistent across studies. More re-
cently, the debate has gained renewed
impetus with the advent of transcath-
eter aortic valve implantation and the
implementation of the valve-in-valve
procedure for degenerated bioprosthe-
ses.2We read with great interest the ar-
ticle by Seiffert and colleagues,3 who
reported their experience with 11 pa-
tients undergoing transcatheter aortic
valve-in-valve implantation. Approxi-
mately half of the study patients had
signs of severe PPM, and the remain-
der had at least moderate PPM, with
the exception of 1 patient, who had
an indexed effective orifice area
greater than 0.85 cm2/m2. In addition,
no significant reduction in transvalvu-
lar gradients was observed after the
procedure in patients with severe
PPM. These results might lead us to
conclude that the procedure was he-
modynamically unsuccessful in 45%
of patients.
The lack of efficacy of the proce-
dure in decreasing aortic valve gradi-
ents is part of a broader controversy
surrounding the optimal treatment
for high-risk patients in the context
of a multidisciplinary management
approach that combines patient needs
and economic resources. As previ-
ously suggested for high-risk patients
by our group,4 we would like to con-
tribute to the debate regarding the
most appropriate valvular procedure
in reoperative surgery by briefly de-
scribing our experience with patients
undergoing reoperative aortic valve
replacement for degenerated biopros-
theses. At our institution, 6 patients
with previous aortic valve replace-
ment underwent implantation with
a Perceval S sutureless valve (Sorin
Group, Saluggia, Italy). Despite their
advanced age at the time of interven-
tion (78.5  4.6 years) and the high
operative risk (logistic EuroSCORE
of 28.5%  20.7%), at 1 year after
implantation all patients are alive
and in good hemodynamic condition
(n¼ 4 in New York Heart Association
class I and n ¼ 2 in New York Heart
Association class II). Notably, theof Thoracic and Cardiovascular Surgesize of the newly implanted valve
was not smaller (22.7 mm vs 23.1
mm), and the indexed effective orifice
area at dischargewas greater than 0.85
cm2/m2 in all patients, with a signifi-
cant reduction in postoperative trans-
valvular gradients (peak gradient
from 75.5  29 mm Hg to 27.5 
3.7 mm Hg; mean gradient from 39.8
 21.6 mm Hg to 14.8  3.3 mm
Hg; P ¼ .031). Although the sample
is limited, these encouraging clinical
and hemodynamic results prompt us
to suggest that sutureless aortic valve
replacement may be considered even
for high-risk patients, in particular
when the diameter of the previously
implanted valve is small, in patients
with small body surface area, or in fe-
male patients.5 At the time of the first
implant, selection of the appropriate
valve size is crucial in the event of
a subsequent valve-in-valve proce-
dure, especially in younger patients.
The valve-in-valve technique is a fea-
sible and promising treatment option,
which is being performed increasingly
in many centers, including our own.
So the real question becomes, is it
worth treating high-risk patients with
this expensive and delicate surgical
procedure if no hemodynamic benefit
will be obtained in approximately
50% of cases?
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